Brokerages Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Price Target at $27.14

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have been assigned an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $27.1429.

A number of equities research analysts have recently weighed in on ZVRA shares. Canaccord Genuity Group cut their price target on Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating for the company in a research note on Monday, July 27th. BTIG Research dropped their price objective on Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating on the stock in a report on Monday, July 27th. HC Wainwright reaffirmed a “buy” rating and set a $26.00 price objective on shares of Zevra Therapeutics in a research report on Thursday, August 20th. Citigroup reiterated an “outperform” rating on shares of Zevra Therapeutics in a research note on Thursday, August 6th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Zevra Therapeutics in a research report on Wednesday, August 19th.

Insider Buying and Selling at Zevra Therapeutics

In related news, Director Corey Watton sold 12,300 shares of Zevra Therapeutics stock in a transaction on Monday, August 10th. The shares were sold at an average price of $11.25, for a total value of $138,375.00. Following the completion of the sale, the director owned 1,800 shares of the company’s stock, valued at approximately $20,250. The trade was a 87.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 3.70% of the company’s stock.

Hedge Funds Weigh In On Zevra Therapeutics

Several hedge funds have recently bought and sold shares of the business. Tidal Investments LLC bought a new position in Zevra Therapeutics during the second quarter valued at about $150,000. WINTON GROUP Ltd boosted its stake in shares of Zevra Therapeutics by 49.0% during the 2nd quarter. WINTON GROUP Ltd now owns 24,335 shares of the company’s stock worth $349,000 after acquiring an additional 8,001 shares in the last quarter. Integrated Wealth Concepts LLC bought a new stake in shares of Zevra Therapeutics during the 2nd quarter worth about $28,000. Wellington Management Group LLP boosted its stake in shares of Zevra Therapeutics by 5.2% during the 2nd quarter. Wellington Management Group LLP now owns 164,538 shares of the company’s stock worth $2,359,000 after acquiring an additional 8,121 shares in the last quarter. Finally, Globeflex Capital L P acquired a new position in shares of Zevra Therapeutics during the 2nd quarter valued at about $2,752,000. 35.03% of the stock is owned by institutional investors and hedge funds.

Zevra Therapeutics Trading Down 3.3%

NASDAQ ZVRA opened at $11.65 on Friday. Zevra Therapeutics has a 1-year low of $7.16 and a 1-year high of $15.03. The firm’s fifty day simple moving average is $11.78 and its 200-day simple moving average is $11.17. The company has a market capitalization of $691.78 million, a PE ratio of 12.66 and a beta of 0.95.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.14. Zevra Therapeutics had a return on equity of 54.54% and a net margin of 42.82%.The firm had revenue of $39.66 million during the quarter, compared to analysts’ expectations of $33.88 million. As a group, analysts predict that Zevra Therapeutics will post 0.72 EPS for the current year.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc is a rare-disease biopharmaceutical company focused on developing and commercializing treatments for conditions with significant unmet medical needs. The company combines data science, patient-focused drug development and traditional pharmaceutical research to advance therapies for rare metabolic and neurological disorders.

Zevra’s lead commercial product is MIPLYFFA (arimoclomol), which the U.S. Food and Drug Administration approved in 2024 for the treatment of Niemann-Pick disease type C in adults and children at least 2 years old, in combination with miglustat.